Physician profile
Kristin Anders
NPI 1114673936
$2,039.67
in general payments reported to CMS, 2019-2025
29 companies · $131 in 2025
The $131 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,418 · 2023: $431 · 2024: $60.15 · 2025: $131.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $588 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $588.12 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $429.36 | 2022-2023 | |
| Lilly USA, LLC | $262.39 | 2022-2023 | Mounjaro |
| Novo Nordisk INC | $204.59 | 2022-2023 | Wegovy, Rybelsus, Ozempic |
| Vanda Pharmaceuticals INC. | $157.13 | 2024-2025 | Fanapt |
| Glaxosmithkline, LLC. | $107.41 | 2022-2023 | Trelegy Ellipta |
| Otsuka America Pharmaceutical, INC. | $87.40 | 2022-2023 | Rexulti |
| Astellas Pharma US INC | $70.80 | 2022-2023 | Myrbetriq |
| Amarin Pharma, INC. | $65.31 | 2022 | |
| Novartis Pharmaceuticals Corporation | $62.29 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.27 | 2022-2023 | Synjardy, Jardiance |
| Janssen Pharmaceuticals, INC | $47.14 | 2022-2023 | Xarelto |
| Biohaven Pharmaceutical Holding Company LTD. | $42.53 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $41.96 | 2022-2023 | Trintellix |
| Astrazeneca Pharmaceuticals LP | $39.79 | 2022-2023 | Farxiga |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $38.74 | 2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $37.17 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $35.62 | 2022 | |
| Becton, Dickinson and Company | $34.00 | 2025 | Introducer Needle |
| Sunovion Pharmaceuticals INC. | $31.26 | 2022 | |
| Sumitomo Pharma America, INC. | $30.42 | 2023 | Gemtesa |
| Ultragenyx Pharmaceutical INC. | $29.93 | 2023 | |
| Currax Pharmaceuticals LLC | $25.84 | 2022 | |
| Ironwood Pharmaceuticals, INC | $17.67 | 2022 | |
| Medtronic, INC. | $17.36 | 2022 | |
| Amgen INC. | $17.13 | 2022 | |
| Pfizer INC. | $16.76 | 2023 | |
| Xeris Pharmaceuticals, INC. | $16.55 | 2023 | Gvoke Hypopen |
| Antares Pharma, INC. | $13.23 | 2022 | |
| Sanofi-Aventis U.S. LLC | $12.62 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristin Anders listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.